Epcoritamab with lenalidomide and rituximab for CNS lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs—epcoritamab, lenalidomide, and rituximab—for people with primary central nervous system lymphoma (PCNSL) that has come back or not responded to treatment. The goal is to see if this three-drug therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have primary diffuse large B-cell lymphoma of the CNS or primary vitreoretinal lymphoma that has come back or not responded to at least one prior treatment.
- You can swallow capsules (no feeding tube).
- You have adequate blood cell counts, kidney function, and liver function (based on blood tests).
- If you are a woman who could become pregnant, you must use two effective birth control methods and have negative pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
This Phase 1/2 study tests how well a combination of pembrolizumab, ibrutinib, and rituximab treats primary CNS lymphoma that came back or didn’t respond after prior brain treatment. It may help shrink the lymphoma and control it in the brain and fluid around the brain.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a combination of the immunotherapy drug pembrolizumab (Keytruda) with standard chemotherapy for people newly diagnosed with primary CNS lymphoma. The goal is to see if adding pembrolizumab can improve outcomes compared to chemotherapy alone.
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
Hear when a new Primary CNS Lymphoma (PCNSL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.